Under 10% of individuals who could benefit from weight-loss injections like Wegovy can access them, warns the World Health Organization as it issues its inaugural guidance on the medications.
Considering in excess of 1,000,000,000 people worldwide now obese, it is urging broader and more equitable availability to this class of drugs.
Per forecasts, more than two billion are projected to be living with obesity by 2030 without intervention.
"The new guidelines acknowledges that obesity is a lifelong illness that can be managed with holistic and ongoing treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are major obstacles to broad access to the jabs that can assist patients in reducing substantial weight, explains the body.
Skinny Jab Scarcity
Even under the current most optimistic outlook, the manufacturing of these medications could only cover approximately 100 million people – under 10% of those who need them, according to the WHO.
The advice urges nations and manufacturers to increase availability, through strategies such as voluntary licensing.
The intellectual property rights on the active ingredient – the main ingredient of a leading brand – is set to lapse in a number of countries in 2026.
How Obesity Injections Function
GLP-1 drugs imitate a natural hormone to delay gastric emptying, curb appetite and increase satiety so users consume fewer calories.
Individuals commonly begin shedding pounds after several weeks of beginning the once-weekly jabs.
Research indicates patients may put most of the weight back on within a year of discontinuing the medication, because their typical hunger resume.
To be overweight or obese raises your likelihood for contracting medical conditions, such as type 2 diabetes, cardiovascular issues, stroke, and certain malignancies.
Excess weight affects people in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, according to the WHO.
